Leidos Holdings (LDOS) Panoramica del titolo
Leidos Holdings, Inc. insieme alle sue consociate, fornisce servizi e soluzioni a clienti governativi e commerciali negli Stati Uniti e a livello internazionale. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 6/6 |
| Crescita futura | 2/6 |
| Prestazioni passate | 2/6 |
| Salute finanziaria | 4/6 |
| Dividendi | 4/6 |
Premi
Analisi del rischio
LDOS Community Fair Values
Create NarrativeSee what 106 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Leidos Holdings, Inc.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$128.86 |
| Massimo di 52 settimane | US$205.77 |
| Minimo di 52 settimane | US$98.86 |
| Beta | 0.57 |
| Variazione di 1 mese | -10.41% |
| Variazione a 3 mesi | 13.45% |
| Variazione di 1 anno | -29.48% |
| Variazione a 3 anni | 37.72% |
| Variazione a 5 anni | 39.72% |
| Variazione dall'IPO | 77.20% |
Notizie e aggiornamenti recenti
Aggiornamento narrativa • Sep 03
LDOS: Cyber And AI Contract Wins Will Balance Health Segment Pressure
Leidos Holdings' updated fair value estimate moves from $110.00 to $125.00 as analysts factor in recent price target revisions around Q2 results, highlighting strength in defense and homeland operations while still accounting for ongoing Health segment uncertainty and competitive pressure. Analyst Commentary Street research on Leidos Holdings around the Q2 earnings cycle shows a split view.
Aggiornamento narrativa • Aug 20
LDOS: Defense And Edge AI Strength Will Offset Health Uncertainty
Leidos Holdings' updated analyst price target has shifted to $156.60 from $165.27 as analysts balance recent Q2 beats and higher targets from several firms with ongoing questions around Health segment pressure and medium term earnings power. Analyst Commentary Recent research on Leidos Holdings highlights a mixed but detailed picture for investors, with views split between those focused on Q2 execution and segment strength and those more cautious about healthcare exposure and medium term earnings power.Recent updates
Aggiornamento narrativa • Sep 03
LDOS: Cyber And AI Contract Wins Will Balance Health Segment Pressure
Leidos Holdings' updated fair value estimate moves from $110.00 to $125.00 as analysts factor in recent price target revisions around Q2 results, highlighting strength in defense and homeland operations while still accounting for ongoing Health segment uncertainty and competitive pressure. Analyst Commentary Street research on Leidos Holdings around the Q2 earnings cycle shows a split view.Aggiornamento narrativa • Aug 20
LDOS: Defense And Edge AI Strength Will Offset Health Uncertainty
Leidos Holdings' updated analyst price target has shifted to $156.60 from $165.27 as analysts balance recent Q2 beats and higher targets from several firms with ongoing questions around Health segment pressure and medium term earnings power. Analyst Commentary Recent research on Leidos Holdings highlights a mixed but detailed picture for investors, with views split between those focused on Q2 execution and segment strength and those more cautious about healthcare exposure and medium term earnings power.
Aggiornamento narrativa • Aug 06
LDOS: AI And Defense Contracts Will Drive Future Repricing Debate
Leidos Holdings' updated analyst price target framework points to a lower fair value of about $203.76 from roughly $213.73, as analysts factor in slightly softer revenue growth and a reduced future P/E multiple, while also reflecting modestly higher margin assumptions and a lower discount rate following recent research updates across the Street. Analyst Commentary Recent research on Leidos Holdings shows a mix of caution and optimism, with several bullish analysts still highlighting potential upside drivers even as many targets move lower.Aggiornamento narrativa • Jul 23
LDOS: AI Logistics Partnerships Will Drive Future Repricing Debate
Leidos Holdings' analyst price target has been reset lower, with a revised fair value estimate moving from $225.00 to about $213.73 as analysts temper revenue growth and valuation expectations while modestly adjusting margin and discount rate assumptions. Analyst Commentary Recent Street research on Leidos Holdings shows a cluster of reduced price targets and rating changes ahead of upcoming earnings updates, with analysts reassessing expectations for revenue trends, healthcare exposure, and execution across key contracts.Seeking Alpha • Jul 14
Leidos Holdings: The Unseen Cash Flow Machine Fueling Aggressive Buybacks In Defense
Summary Leidos is deeply undervalued, with a STRONG BUY rating supported by robust free cash flow and an asset-light business model. LDOS benefits from inelastic, recession-proof government defense spending, long-term cost-plus contracts, and high revenue visibility via a substantial backlog. Segment restructuring reveals a blend of stable, inflation-indexed government revenue and high-margin health & civil operations, enhancing cash flow and resilience. DCF, relative, and dividend models all indicate 96–315% upside potential, with significant margin of safety even in pessimistic scenarios. Read the full article on Seeking AlphaAggiornamento narrativa • Jul 09
LDOS: AI Contracts And Defense Wins Will Offset Healthcare Headwinds
The analyst price target for Leidos Holdings has been reduced by about $13, reflecting updated assumptions for slightly lower revenue growth, a marginally higher discount rate, modestly softer profit margins, and a lower future P/E multiple as analysts factor in pressures in the healthcare portfolio and adopt more cautious expectations for organic growth. Analyst Commentary Recent Street research on Leidos Holdings shows a split view, with some bullish analysts still positive on the company’s long term growth and others turning more cautious as they rethink expectations around organic growth, healthcare exposure, and valuation multiples.Nuova narrativa • Jul 02
AI And Cyber Pipelines Will Shape A Balanced Long Term Outlook
Catalysts About Leidos Holdings Leidos Holdings is a technology and engineering company that provides solutions in defense, intelligence, health, and infrastructure, primarily for U.S. government customers. What are the underlying business or industry changes driving this perspective?Aggiornamento narrativa • Jun 25
LDOS: Healthcare Headwinds Will Set Up Future Re Rating Opportunity
The updated analyst price target framework for Leidos Holdings edges lower, with fair value moving from $183.27 to $178.27 as analysts factor in recent downgrades, reduced targets tied to healthcare contract pressure, and more cautious assumptions for organic growth, margins, and future P/E. Analyst Commentary Recent Street research on Leidos Holdings has tilted more cautious, with several bearish analysts revisiting ratings and price targets as they reassess healthcare exposure, organic growth expectations, and earnings power.Nuova narrativa • Jun 17
Leidos Stock Will Ride NorthStar 2030 And AI Missions For Long-Term Upside
Catalysts About Leidos Holdings Leidos Holdings is a technology-focused defense, intelligence, health, and infrastructure company that delivers mission-critical systems, services, and products to government and commercial customers. What are the underlying business or industry changes driving this perspective?Articolo di analisi • Jun 17
Leidos Holdings (LDOS) Stock Could Be 38% Undervalued After Downgrade And DHA Contract Pressure
Leidos Holdings (LDOS) is back in focus after a Jefferies downgrade and fresh concerns about profit margins and U.S. defense budgets, along with additional pressure from changes to a key Defense Health Agency contract. See our latest analysis for Leidos Holdings. Leidos Holdings has come under pressure, with the share price down 31.9% over the past 90 days and the 1 year total shareholder return declining 23.2%, although the 3 year total shareholder return of 38.0% still reflects earlier...Aggiornamento narrativa • Jun 10
LDOS: Hypersonic Weapons Production Contract Will Drive Future Re Rating Potential
Analysts have trimmed their fair value estimate for Leidos Holdings by about $3 to $183.27, reflecting lower organic growth and profit margin assumptions after several firms cut price targets, including a Jefferies downgrade to Hold and reduced long term EPS expectations. This was partly offset by fresh positive coverage such as an Outperform initiation at BNP Paribas with a $165 target.Aggiornamento narrativa • May 27
LDOS: Federal IT Wins And Hypersonic Programs Will Support Re Rating
Leidos Holdings' analyst price target has been revised lower by roughly $13 to about $186, as analysts update their models for a higher discount rate, a lower future P/E, and refreshed views from recent target cuts and a neutral initiation alongside one target increase. Analyst Commentary Recent Street research on Leidos Holdings has centered on recalibrated price targets, with several reductions and one increase, along with a fresh neutral initiation.Aggiornamento narrativa • May 02
LDOS: Defense Tech Contracts And AI Alliance Will Offset 2026 VBA Drag
The updated analyst price target for Leidos Holdings has been trimmed by about $5 to roughly $199 per share. Analysts factored in recent target cuts around mixed Q4 results, modestly lower revenue growth assumptions, a slightly higher discount rate, and a somewhat lower future P/E multiple, even as profit margin expectations edge up.Aggiornamento narrativa • Apr 17
LDOS: Defense Tech And AI Partnership Will Offset 2026 VBA Headwinds
Leidos Holdings' updated analyst price target has moved lower by about $5 per share to reflect a slightly higher discount rate, a reduced future P/E assumption, and tempered margin expectations, as analysts factor in mixed Q4 results, recent target cuts from several firms, and ongoing headwinds in Veterans Benefits Administration work, even as growth initiatives continue. Analyst Commentary Recent research updates on Leidos point to a more cautious valuation framework, even as some analysts still see upside tied to growth investments and capital allocation changes.Aggiornamento narrativa • Apr 03
LDOS: Defense Tech And AI Contracts Will Offset 2026 VBA Slowdown
Analysts have trimmed the average price target for Leidos Holdings to $209 from about $212, reflecting slightly higher discount rate assumptions, modestly adjusted growth and margin expectations, and mixed reactions to recent Q4 results and contract headwinds. Analyst Commentary Recent research paints a mixed picture around Leidos Holdings, with both optimistic and cautious views emerging after the latest Q4 report, updated guidance, and evolving contract exposure.Aggiornamento narrativa • Mar 19
LDOS: Defense Tech And AI Expansion Will Offset 2026 VBA Contract Slowdown
Analysts have trimmed the blended price target on Leidos Holdings by about $1.50 to roughly $212.50, reflecting slightly softer long term growth and margin assumptions after mixed Q4 results and evolving views on the VBA headwind and defense tech opportunities. Analyst Commentary Street research on Leidos Holdings has shifted toward a more balanced view, with price targets generally nudged lower and ratings clustered around Buy, Outperform, Hold, and Neutral.Aggiornamento narrativa • Mar 05
LDOS: Defense Tech And AI Shift Will Offset 2026 VBA Headwinds
Analysts have reduced their blended price target for Leidos Holdings by about $4 to roughly $214, reflecting recent Q4 updates, mixed views on growth in 2026, and ongoing debate around the impact of slower Veterans Benefits Administration work versus opportunities in defense tech and other growth segments. Analyst Commentary Street research on Leidos presents a split view, with several firms trimming price targets after Q4 while still highlighting long term growth opportunities in defense technology and other higher growth areas.Aggiornamento narrativa • Feb 18
LDOS: Defense Tech And AI Shift Will Support Premium Multiple
The updated fair value estimate for Leidos Holdings edges down to about $218 per share from roughly $219, as analysts adjust price targets lower, citing mixed Q4 results, a slowdown in Veterans Benefits Administration activity, and tempered views on future valuation and guidance, even as the company increases its focus on higher growth markets. Analyst Commentary Recent Street research on Leidos points to a split view, with some analysts focusing on long term growth opportunities and others stressing execution risks and valuation constraints following the latest Q4 report and guidance.Aggiornamento narrativa • Feb 04
LDOS: Entrust Acquisition And AI Partnerships Will Support Premium Multiple
Analysts nudged their blended price target on Leidos Holdings slightly higher to about US$219.31, reflecting a modestly higher assumed future P/E multiple while balancing recent target moves tied to enthusiasm around the Entrust acquisition and caution over potential 2026 contract headwinds. Analyst Commentary Recent research on Leidos highlights a split view, with some analysts leaning into the potential of the Entrust acquisition and others more focused on contract concentration and 2026 risk.Aggiornamento narrativa • Jan 21
LDOS: Health And Civil Strength And VA Contract Risk Will Shape Premium Multiple
Narrative Update: Leidos Holdings Analysts have trimmed their blended price target on Leidos Holdings by about $1 per share to $219, reflecting slightly more conservative assumptions on revenue growth, margins, and future P/E, after balancing recent target increases from firms citing strong execution and portfolio positioning with concerns around a key high margin contract and the timing of proving its sustainability. Analyst Commentary Recent research on Leidos highlights a mix of optimism around the core business and caution around a key contract that could affect medium term growth and valuation multiples.Aggiornamento narrativa • Jan 07
LDOS: Health And Civil Strength And Pipeline Visibility Will Support Premium Multiple
Analysts have nudged their fair value estimate for Leidos Holdings higher to about $219.85 from roughly $218.08, citing stronger recent earnings, solid Health & Civil margins, a 1.3x book to bill, a US$69b near term pipeline, and a view that the company merits a premium P/E multiple within government services. Analyst Commentary Bullish Takeaways Bullish analysts see the recent earnings beat as support for a higher fair value, pointing to execution in Health & Civil margins as a key driver of profitability.Aggiornamento narrativa • Dec 16
LDOS: Strong Health And Civil Margins Will Support Future Premium Multiple
Analysts have raised their price target on Leidos Holdings to approximately $218.08 per share from about $218.08. This reflects slightly stronger expectations for revenue growth and sustained margins, supported by robust book to bill trends, a sizable near term pipeline, and upside earnings performance with higher profitability guidance into 2025.Aggiornamento narrativa • Dec 02
LDOS: Strong Health And Civil Margins Will Support Continued Margin Upside
Leidos Holdings saw its average analyst price target rise from $210 to $230 as analysts highlighted robust Health & Civil margins, a strong contract pipeline, and increased profitability guidance following recent earnings results. Analyst Commentary Recent analyst reports have highlighted several factors influencing sentiment around Leidos Holdings following the latest earnings results and guidance updates.Aggiornamento narrativa • Nov 18
LDOS: Near-Term Contract Pipeline Will Drive Continued Margin Upside
Leidos Holdings' analyst price target has increased from $201.83 to $218.08 per share, as analysts cite strong margins in Health and Civil segments, a robust $69 billion pipeline, and raised profitability guidance as driving factors for the upward revision. Analyst Commentary Recent analyst reports have highlighted several factors that shape both the bullish and cautious outlooks for Leidos Holdings following its stronger-than-expected earnings performance and revised guidance.Articolo di analisi • Nov 06
Leidos Holdings (NYSE:LDOS) Is Increasing Its Dividend To $0.43
Leidos Holdings, Inc. ( NYSE:LDOS ) will increase its dividend from last year's comparable payment on the 31st of...Aggiornamento narrativa • Nov 02
LDOS: Federal Health And Security Spending Will Drive Steady Performance Ahead
Leidos Holdings saw its analyst price target rise from approximately $198.50 to $201.83. Analysts cited the company’s ongoing momentum in health services, robust margins, and its positioning to benefit from expanding federal funding priorities.Aggiornamento narrativa • Oct 18
Government Funding And Digital Transformation Will Create Future Value
The average analyst price target for Leidos Holdings was raised by approximately $4 to $198.50. Analysts highlighted improving healthcare margins, stronger execution in health and defense services, and the company's positioning to benefit from recent government funding priorities.Aggiornamento narrativa • Oct 04
Government Funding And Digital Transformation Will Create Future Value
The analyst price target for Leidos Holdings has been increased by approximately $2 to $194.71, as analysts cite ongoing strength in healthcare margins, opportunities in defense solutions, and improved business execution as key factors supporting the higher valuation. Analyst Commentary Recent Street research updates reflect a generally positive outlook on Leidos Holdings, with multiple analysts raising their price targets and upgrading the stock in response to improved business execution and strong performance in key sectors.Aggiornamento narrativa • Sep 19
Government Funding And Digital Transformation Will Create Future Value
Upward analyst revisions for Leidos Holdings reflect confidence in its strategic investments in health and border security, strong healthcare margins, and effective leadership, resulting in a modest price target increase from $190.15 to $192.66. Analyst Commentary Bullish analysts highlight Leidos' strategic investments in veteran health, border security, and autonomous maritime, positioning the company to benefit from new government funding priorities.Aggiornamento narrativa • Sep 04
Government Funding And Digital Transformation Will Create Future Value
Analysts maintain a positive outlook on Leidos Holdings due to strong execution in Health Services, favorable positioning for government funding priorities, increased management confidence, and a strategic pivot toward higher-margin growth sectors, resulting in an unchanged $186.69 price target. Analyst Commentary Continued strength and solid execution within Leidos' Health Services business, contributing to improved outlook and confidence.Rendimenti per gli azionisti
| LDOS | US Professional Services | US Mercato | |
|---|---|---|---|
| 7D | -3.1% | -3.6% | -0.9% |
| 1Y | -29.5% | -14.4% | 13.9% |
Ritorno vs Industria: LDOS ha avuto una performance inferiore rispetto al US Professional Services che ha registrato un rendimento -14.4 % nell'ultimo anno.
Rendimento vs Mercato: LDOS ha avuto una performance inferiore al mercato US che ha registrato un rendimento 13.9 % nell'ultimo anno.
Volatilità dei prezzi
| LDOS volatility | |
|---|---|
| LDOS Average Weekly Movement | 5.9% |
| Professional Services Industry Average Movement | 8.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Prezzo delle azioni stabile: LDOS non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 6% ) di LDOS è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1969 | 50,000 | Tom Bell | www.leidos.com |
Leidos Holdings, Inc. insieme alle sue controllate, fornisce servizi e soluzioni per clienti governativi e commerciali negli Stati Uniti e a livello internazionale. Il segmento Sicurezza nazionale e digitale fornisce software per la sicurezza nazionale; servizi che utilizzano l'intelligenza artificiale e l'apprendimento automatico per coordinare mare, terra, aria e spazio per aiutare i combattenti; soluzioni per operazioni informatiche offensive, difensive e fisiche; analisi di intelligence, supporto operativo, operazioni logistiche, sicurezza, linguistica, produzione di forze, biometria, chimica, biologica, radiologica, nucleare, esplosivi, energia, formazione e altri servizi; e servizi di modernizzazione e trasformazione digitale. Il segmento Health & Civil offre sistemi di controllo del traffico aereo, software per missioni sanitarie, servizi sanitari gestiti, gestione e funzionamento delle infrastrutture, operazioni logistiche e supporto informatico e servizi di supporto alla ricerca e allo sviluppo nel campo delle scienze della vita.
Leidos Holdings, Inc. Riepilogo dei fondamenti
| LDOS statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$16.17b |
| Utili (TTM) | US$1.38b |
| Ricavi(TTM) | US$17.63b |
11.8x
Rapporto P/E0.9x
Rapporto P/SLDOS è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| LDOS Conto economico (TTM) | |
|---|---|
| Ricavi | US$17.63b |
| Costo del fatturato | US$14.50b |
| Profitto lordo | US$3.14b |
| Altre spese | US$1.76b |
| Utili | US$1.38b |
Ultimi utili riportati
Jul 03, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | 10.96 |
| Margine lordo | 17.80% |
| Margine di profitto netto | 7.80% |
| Rapporto debito/patrimonio netto | 112.2% |
Come si è comportato LDOS nel lungo periodo?
Vedi performance storica e confrontoDividendi
1.3%
Rendimento attuale del dividendo16%
Rapporto di remunerazioneLDOS paga dividendi affidabili?
Vedere la storia dei dividendi e i benchmark di LDOS| Leidos Holdings date dei dividendi | |
|---|---|
| Data di stacco del dividendo | Sep 15 2026 |
| Data di pagamento dei dividendi | Sep 30 2026 |
| Giorni fino al dividendo Ex | 0 days |
| Giorni prima della data di pagamento dei dividendi | 15 days |
LDOS paga dividendi affidabili?
Vedere la storia dei dividendi e i benchmark di LDOSAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/09/14 18:37 |
| Prezzo dell'azione a fine giornata | 2026/09/11 00:00 |
| Utili | 2026/07/03 |
| Utili annuali | 2026/01/02 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Leidos Holdings, Inc. è coperta da 24 analisti. 16 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| John Eade | Argus Research Company |
| Peter Arment | Baird |
| David Strauss | Barclays |